CN108473500B - 用作IL-12、IL-23和/或IFNα响应的调节剂的咪唑并哒嗪化合物 - Google Patents

用作IL-12、IL-23和/或IFNα响应的调节剂的咪唑并哒嗪化合物 Download PDF

Info

Publication number
CN108473500B
CN108473500B CN201680079065.7A CN201680079065A CN108473500B CN 108473500 B CN108473500 B CN 108473500B CN 201680079065 A CN201680079065 A CN 201680079065A CN 108473500 B CN108473500 B CN 108473500B
Authority
CN
China
Prior art keywords
alkyl
group
heteroaryl
bicyclic
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680079065.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN108473500A (zh
Inventor
D·S·温斯坦
R·M·莫斯林
Y·张
D·S·加德纳
J·B·圣泰拉
C·M·兰格维内
S·斯达胡拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN108473500A publication Critical patent/CN108473500A/zh
Application granted granted Critical
Publication of CN108473500B publication Critical patent/CN108473500B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201680079065.7A 2015-11-18 2016-11-17 用作IL-12、IL-23和/或IFNα响应的调节剂的咪唑并哒嗪化合物 Active CN108473500B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562256784P 2015-11-18 2015-11-18
US62/256,784 2015-11-18
US201662404827P 2016-10-06 2016-10-06
US62/404,827 2016-10-06
PCT/US2016/062396 WO2017087590A1 (en) 2015-11-18 2016-11-17 Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses

Publications (2)

Publication Number Publication Date
CN108473500A CN108473500A (zh) 2018-08-31
CN108473500B true CN108473500B (zh) 2021-06-08

Family

ID=57472068

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680079065.7A Active CN108473500B (zh) 2015-11-18 2016-11-17 用作IL-12、IL-23和/或IFNα响应的调节剂的咪唑并哒嗪化合物

Country Status (7)

Country Link
US (1) US10479793B2 (https=)
EP (1) EP3377496B1 (https=)
JP (1) JP6843135B2 (https=)
KR (1) KR102782807B1 (https=)
CN (1) CN108473500B (https=)
ES (1) ES2828733T3 (https=)
WO (1) WO2017087590A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170333435A1 (en) 2014-11-06 2017-11-23 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
US20180185368A1 (en) 2014-11-06 2018-07-05 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
EP4406616A3 (en) 2014-11-06 2024-11-06 Bial-R&D Investments, S.A. Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
CA3020305A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
EP3440081A4 (en) 2016-04-06 2019-09-18 Lysosomal Therapeutics Inc. PYRROLO [1,2-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER
AU2017246455B2 (en) 2016-04-06 2021-09-30 Bial - R&D Investments, S.A. Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
KR102530515B1 (ko) 2016-05-05 2023-05-09 비알 - 알&디 인베스트먼츠, 에스.에이. 치환된 이미다조[1,2-b]피리다진, 치환된 이미다조[1,5-b]피리다진, 관련 화합물, 및 의학적 장애의 치료에서의 그의 용도
ES2902995T3 (es) * 2016-10-07 2022-03-30 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
EP3541817B1 (en) * 2016-11-17 2020-12-23 Bristol-Myers Squibb Company Imidazopyridazine modulators of il-12, il-23 and/or ifn-alpha
SI3658557T1 (sl) * 2017-07-28 2024-10-30 Takeda Pharmaceutical Company Limited Zaviralci TYK2 in njihova uporaba
AR117398A1 (es) 2018-03-12 2021-08-04 Abbvie Inc Inhibidores de la señalización mediada por tirosina cinasa 2
JP7179161B2 (ja) * 2018-09-10 2022-11-28 イーライ リリー アンド カンパニー 乾癬および全身性エリテマトーデスの処置に有用なピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミド誘導体
JP7631193B2 (ja) 2018-10-22 2025-02-18 アルミス インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
AR117177A1 (es) 2018-12-10 2021-07-14 Lilly Co Eli DERIVADOS DE 7-(METILAMINO)PIRAZOLO[1,5-A]PIRIMIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE IL-23 E INFa
TWI752400B (zh) * 2019-01-07 2022-01-11 美商美國禮來大藥廠 Il-17a抑制劑
CN113348021B (zh) * 2019-01-23 2025-07-11 武田药品工业株式会社 Tyk2抑制剂和其用途
JP2022519696A (ja) * 2019-02-07 2022-03-24 ベンティックス バイオサイエンシーズ，インク． Ｔｙｋ２偽キナーゼリガンド
US12473290B2 (en) 2019-03-05 2025-11-18 Bristol Myers-Squibb Company Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
CA3132632A1 (en) * 2019-03-11 2020-09-17 Esker Therapeutics, Inc. Tyk2 inhibitors and uses thereof
TWI810520B (zh) 2020-02-12 2023-08-01 美商美國禮來大藥廠 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺化合物
CN115052660B (zh) 2020-02-12 2024-01-09 伊莱利利公司 取代的7-(甲氨基)吡唑并[1,5-a]嘧啶-3-甲酰胺衍生物
CN115867348B (zh) * 2020-04-30 2025-05-06 詹森药业有限公司 作为il-17调节剂的咪唑并嘧啶
PE20230469A1 (es) * 2020-04-30 2023-03-14 Janssen Pharmaceutica Nv Imidazopiridazinas como moduladores de il-17
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
CN115916207A (zh) * 2020-08-20 2023-04-04 轶诺(浙江)药业有限公司 一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途
EP4214215A1 (en) * 2020-09-16 2023-07-26 Alumis Inc. Tyk2 inhibitors and uses thereof
WO2022156657A1 (en) * 2021-01-19 2022-07-28 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Imidazolopyridazine or pyrazolopyrimidine compounds and compositions
CA3213816A1 (en) 2021-03-16 2022-09-22 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Amino heteroaryl compounds and compositions
EP4423086A1 (en) 2021-10-25 2024-09-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
CN118580191A (zh) * 2022-01-28 2024-09-03 和记黄埔医药（上海）有限公司 用于制备咪唑并[1,2-b]哒嗪类化合物的中间体
WO2025168035A1 (zh) * 2024-02-07 2025-08-14 合肥羿科医药有限公司 杂环类化合物、其药物组合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
CN101730699A (zh) 2007-03-21 2010-06-09 百时美施贵宝公司 可用于治疗增殖性、变应性、自身免疫性和炎症性疾病的稠合杂环化合物
EP2217601A1 (en) * 2007-11-08 2010-08-18 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyridazines for use as protein kinase inhibitors
WO2009100375A1 (en) 2008-02-06 2009-08-13 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
JP6073343B2 (ja) * 2011-10-20 2017-02-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ
WO2013134219A1 (en) * 2012-03-09 2013-09-12 Lexicon Pharmaceuticals, Inc. Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
ES2702126T3 (es) * 2013-12-10 2019-02-27 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa

Also Published As

Publication number Publication date
US10479793B2 (en) 2019-11-19
JP6843135B2 (ja) 2021-03-17
US20180325899A1 (en) 2018-11-15
ES2828733T3 (es) 2021-05-27
KR20180081584A (ko) 2018-07-16
EP3377496A1 (en) 2018-09-26
WO2017087590A1 (en) 2017-05-26
JP2019501125A (ja) 2019-01-17
CN108473500A (zh) 2018-08-31
EP3377496B1 (en) 2020-09-16
KR102782807B1 (ko) 2025-03-14

Similar Documents

Publication Publication Date Title
CN108473500B (zh) 用作IL-12、IL-23和/或IFNα响应的调节剂的咪唑并哒嗪化合物
AU2023255024B2 (en) Sulfone pyridine alkyl amide-substituted heteroaryl compounds
CN110036015B (zh) 可用作IL-12、IL-23和/或IFNα应答的调节剂的咪唑并哒嗪化合物
AU2014347275B2 (en) Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNalpha responses
EP3917912B1 (en) Amide-disubstituted pyridine or pyridazine compounds
AU2019373203A1 (en) Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha
WO2021222153A1 (en) Substituted n-(methyl-d3)pyridazine-3-carboxamide or n-(methyl-d3)-nicotinamide compounds as il-12, il-23 and/or ifnalpha modulators
CN104903301B (zh) 可用于调节IL‑12、IL‑23和/或IFNα的烷基酰胺取代的嘧啶化合物
CN110191887B (zh) IL-12、IL-23和/或IFN-α的咪唑并哒嗪调节剂
WO2018111787A1 (en) Phosphine oxide alkyl amide substituted heteroaryl compounds as modulators of il-12, il-23, and/or ifn alpha responses
WO2022241175A1 (en) Substituted heterocyclic compounds
CN114222744B (zh) 可用作IL-12、IL-23和/或IFNα反应调节剂的咪唑并哒嗪化合物
HK1226400B (en) Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnalpha responses

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant